An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2013
Price : $35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2013 Planned end date changed from 1 Feb 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 24 Oct 2012 Planned End Date changed from 1 Aug 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.